How much profit has Geneuro made this year?
Geneuro has made -12.33 M EUR this year.
Geneuro Net Income 2024
Geneuro Net Income
-12.33 M EUR
Ticker
GNRO.PA
ISIN
CH0308403085
WKN
A2AHDP
In 2024, Geneuro's profit amounted to -12.33 M EUR, a -16.44% increase from the -14.76 M EUR profit recorded in the previous year.
The Geneuro Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2025e | -7.81 |
| 2024e | -12.33 |
| 2023 | -14.76 |
| 2022 | -12.2 |
| 2021 | -6.82 |
| 2020 | -8.96 |
| 2019 | -9.46 |
| 2018 | -8.33 |
| 2017 | -5.84 |
| 2016 | -14.1 |
| 2015 | -4.49 |
| 2014 | 1.78 |
| 2013 | -3.5 |
Geneuro Revenue, EBIT, Net Income CH0308403085 · A2AHDP
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Geneuro, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Geneuro from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Geneuro’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Geneuro. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Geneuro’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Geneuro’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Geneuro’s growth potential.
Geneuro Revenue, EBIT and net profit per share
| Date | Geneuro Revenue | Geneuro EBIT | Geneuro Net Income |
|---|---|---|---|
| 2025e | 11.03 M EUR | -9.76 M EUR | -7.81 M EUR |
| 2024e | 0 EUR | -10.91 M EUR | -12.33 M EUR |
| 2023 | 0 EUR | -14.36 M EUR | -14.76 M EUR |
| 2022 | 0 EUR | -11.23 M EUR | -12.2 M EUR |
| 2021 | 0 EUR | -6.37 M EUR | -6.82 M EUR |
| 2020 | 0 EUR | -7.46 M EUR | -8.96 M EUR |
| 2019 | 0 EUR | -8.99 M EUR | -9.46 M EUR |
| 2018 | 7.46 M EUR | -8.09 M EUR | -8.33 M EUR |
| 2017 | 14.95 M EUR | -5.74 M EUR | -5.84 M EUR |
| 2016 | 5.92 M EUR | -14.04 M EUR | -14.1 M EUR |
| 2015 | 2.54 M EUR | -4.32 M EUR | -4.49 M EUR |
| 2014 | 7.31 M EUR | 2.2 M EUR | 1.78 M EUR |
| 2013 | 20,000 EUR | -3.35 M EUR | -3.5 M EUR |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 20,000 EUR | -3.35 M EUR | -3.5 M EUR |
| 2014 | 7.31 M EUR | 2.2 M EUR | 1.78 M EUR |
| 2015 | 2.54 M EUR | -4.32 M EUR | -4.49 M EUR |
| 2016 | 5.92 M EUR | -14.04 M EUR | -14.1 M EUR |
| 2017 | 14.95 M EUR | -5.74 M EUR | -5.84 M EUR |
| 2018 | 7.46 M EUR | -8.09 M EUR | -8.33 M EUR |
| 2019 | 0 EUR | -8.99 M EUR | -9.46 M EUR |
| 2020 | 0 EUR | -7.46 M EUR | -8.96 M EUR |
| 2021 | 0 EUR | -6.37 M EUR | -6.82 M EUR |
| 2022 | 0 EUR | -11.23 M EUR | -12.2 M EUR |
| 2023 | 0 EUR | -14.36 M EUR | -14.76 M EUR |
| 2024e | 0 EUR | -10.91 M EUR | -12.33 M EUR |
| 2025e | 11.03 M EUR | -9.76 M EUR | -7.81 M EUR |
Geneuro stock margins CH0308403085 · A2AHDP
The Geneuro margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Geneuro. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Geneuro.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Geneuro's sales revenue. A higher gross margin percentage indicates that the Geneuro retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Geneuro's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Geneuro's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Geneuro's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Geneuro. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Geneuro's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Geneuro Margin History
| Geneuro Gross margin | Geneuro Profit margin | Geneuro EBIT margin | Geneuro Profit margin |
|---|---|---|---|
| 2025e | 0 % | -88.56 % | -70.88 % |
| 2024e | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | -108.38 % | -111.59 % |
| 2017 | 0 % | -38.4 % | -39.05 % |
| 2016 | 0 % | -237.21 % | -238.33 % |
| 2015 | 0 % | -170.23 % | -176.71 % |
| 2014 | 0 % | 30.13 % | 24.32 % |
| 2013 | 0 % | -16,750 % | -17,500 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 0 % | -16,750 % | -17,500 % |
| 2014 | 0 % | 30.13 % | 24.32 % |
| 2015 | 0 % | -170.23 % | -176.71 % |
| 2016 | 0 % | -237.21 % | -238.33 % |
| 2017 | 0 % | -38.4 % | -39.05 % |
| 2018 | 0 % | -108.38 % | -111.59 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2025e | 0 % | -88.56 % | -70.88 % |
Geneuro Aktienanalyse
What does Geneuro do?
Geneuro SA is a biopharmaceutical company based in Plan-les-Ouates, Geneva, Switzerland. It was founded in 2007 and focuses on the development of innovative therapies for autoimmune diseases and other neurological disorders. Geneuro was founded based on research by Prof. Jean-Michel Goust, a renowned pain therapist and neuroimmunologist. In collaboration with distinguished scientists and experts in the field of neuroimmunology and neurovirology, he developed a new concept for combating autoimmune diseases of the nervous system, such as multiple sclerosis. Geneuro's business model is centered around developing novel therapeutics for chronic neurological disorders, particularly through immunomodulation. The drugs aim to help regulate the body's immune system to suppress inflammatory reactions in the brain, thereby preventing or at least reducing the adverse effects of autoimmune diseases. The company divides its activities into two main areas: research and development of novel therapeutics, and marketing of products. In the research and development field, Geneuro works closely with various partners such as universities, research institutes, and other companies. The aim is to translate the latest scientific knowledge in the fields of neuroimmunology and neurovirology into clinical practice in order to provide patients with better treatment options. Geneuro has focused on a specific class of drugs known as "anti-HERV," which stands for "human endogenous retroviruses." These retroviral particles make up approximately five percent of the human genome and are currently an active research area in neuroimmunology. Geneuro has developed a method to produce specific antibodies against these retroviruses and utilizes these antibodies as therapeutics in the fight against autoimmune diseases. The leading product of Geneuro in this area is GNbAC1, a novel monoclonal antibody preparation against the HERV virus, which was developed in collaboration with Merck Serono. GNbAC1 is currently in the clinical testing phase (Phase III) and has already shown promising results. It demonstrates significant efficacy in the treatment of multiple sclerosis and is also being tested for the treatment of other neuroimmunological diseases such as neuromyelitis optica and amyotrophic lateral sclerosis. In addition to GNbAC1, Geneuro has other products in the development phase. These include GNbAC2, a product specifically developed for the Japanese market in collaboration with Toyama Chemical Co., Ltd., and GNbAC-K9, a product for dogs designed to treat degenerative central nervous system disorders. Geneuro's second business area involves the marketing of its products. The company collaborates with both large pharmaceutical companies and smaller biotech companies worldwide to broaden the reach of their products. In recent years, Geneuro has established itself as a significant player in the field of neurological disorders. The company has developed promising therapies for autoimmune diseases that regulate the body's immune system in an innovative way. Geneuro's antibody preparations aim to target a specific class of proteins to contain inflammation in the brain and achieve broader efficacy in the treatment of neurological diseases such as MS. The company has set ambitious goals to improve its products and enhance its innovation capabilities, and will continue to drive significant developments in the future. Geneuro ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Geneuro's Profit Margins
The profit margins of Geneuro represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Geneuro's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Geneuro's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Geneuro's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Geneuro’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Geneuro stock
How has the profit developed compared to last year?
The profit has increased by -16.44% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Geneuro publish its earnings?
Geneuro publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Geneuro?
The profits of Geneuro are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Geneuro?
You can learn more about the earnings of Geneuro by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Geneuro pay?
Over the past 12 months, Geneuro paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geneuro is expected to pay a dividend of 0 EUR.
What is the dividend yield of Geneuro?
The current dividend yield of Geneuro is .
When does Geneuro pay dividends?
Geneuro pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Geneuro?
Geneuro paid dividends every year for the past 0 years.
What is the dividend of Geneuro?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Geneuro located?
Geneuro is assigned to the 'Health' sector.
Wann musste ich die Aktien von Geneuro kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Geneuro from 8/25/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.
When did Geneuro pay the last dividend?
The last dividend was paid out on 8/25/2024.
What was the dividend of Geneuro in the year 2023?
In the year 2023, Geneuro distributed 0 EUR as dividends.
In which currency does Geneuro pay out the dividend?
The dividends of Geneuro are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Geneuro
Our stock analysis for Geneuro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geneuro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
